Free Trial
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Lyra Therapeutics logo
$7.00 -0.05 (-0.71%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$7.04 +0.04 (+0.50%)
As of 08/29/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Key Stats

Today's Range
$6.94
$7.15
50-Day Range
$6.58
$13.38
52-Week Range
$3.81
$37.50
Volume
6,056 shs
Average Volume
16,200 shs
Market Capitalization
$11.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.00
Consensus Rating
Hold

Company Overview

Lyra Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

LYRA MarketRank™: 

Lyra Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 442nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Lyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lyra Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyra Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lyra Therapeutics has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lyra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.95% of the float of Lyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyra Therapeutics has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lyra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lyra Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.95% of the float of Lyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyra Therapeutics has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lyra Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,039.00 in company stock.

  • Percentage Held by Insiders

    Only 3.25% of the stock of Lyra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lyra Therapeutics' insider trading history.
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LYRA Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Lyra Therapeutics Posts 85% Q2 Loss Drop
Lyra Therapeutics Board Chair Waksal Steps Down
See More Headlines

LYRA Stock Analysis - Frequently Asked Questions

Lyra Therapeutics' stock was trading at $10.32 at the beginning of 2025. Since then, LYRA stock has decreased by 32.2% and is now trading at $7.00.

Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its earnings results on Tuesday, August, 12th. The company reported ($5.51) EPS for the quarter, topping analysts' consensus estimates of ($5.79) by $0.28. The business had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.18 million. Lyra Therapeutics had a negative net margin of 5,043.64% and a negative trailing twelve-month return on equity of 404.56%.

Lyra Therapeutics shares reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

Lyra Therapeutics' top institutional investors include Perceptive Advisors LLC (15.56%), Bank of America Corp DE (1.74%) and Geode Capital Management LLC (0.69%). Insiders that own company stock include Maria Palasis, Jason Cavalier, Perceptive Advisors Llc, Nbvm Gp, Llc and Harlan Waksal.
View institutional ownership trends
.

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

Last Earnings
8/12/2025
Today
8/30/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LYRA
CIK
1327273
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$100.00
Potential Upside/Downside
+1,328.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($29.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$93.43 million
Net Margins
-5,043.64%
Pretax Margin
-5,041.17%
Return on Equity
-404.56%
Return on Assets
-60.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.78
Quick Ratio
2.78

Sales & Book Value

Annual Sales
$1.53 million
Price / Sales
7.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.99 per share
Price / Book
7.07

Miscellaneous

Outstanding Shares
1,640,000
Free Float
1,592,000
Market Cap
$11.48 million
Optionable
Optionable
Beta
0.16

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:LYRA) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners